Javelin Pharmaceuticals, Inc described its initial review of top line results from a phase-III study of Ereska (intranasal ketamine 30mg). This randomized, multicenter, double-blind, 1:1 placebo-controlled study assessed the safety and analgesic efficacy of repeated doses of Ereska over six hours in 259 patients with acute moderate-to-severe pain following orthopaedic surgery
The details can be read here.
No comments:
Post a Comment